Optimizing the Route to Regulatory Approval for a Novel Vaccine
The rapid delivery of safe and effective vaccines is critical, clearly demonstrated by COVID-19 pandemic. Streamlining vaccine development through novel trial design is essential for expediting the process. This paper presents key insights on optimizing the path to regulatory approval, with a focus on:
- Early phase studies: To optimize the development of new vaccines, it is crucial to leverage multidisciplinary expertise and include multiple exploratory endpoints. Human challenge studies can be valuable when dealing with mild or treatable infections. Case examples from the literature illustrate the application of these strategies.
- Immune correlates and immuno-bridging: The concepts of immune correlates and immuno-bridging are discussed with example of circumstances when these might be applied in lieu of clinical effectiveness studies.
- Considerations for later phase studies: The challenges associated with clinical effectiveness trials are discussed as well as approaches to accelerate vaccine development such as adaptive trial designs together with examples.
- Generating safety data: The regulatory expectations for safety data are discussed along with examples of known and potential risks to be addressed both pre- and post-approval, including the potential for vaccines to exacerbate subsequent infections
- Population diversity: Addressing population diversity in vaccine development is critical. Factors such as ethnicity, socioeconomic status, nutrition, and gut biota can influence vaccine effectiveness and safety.
Related Insights
Blog
Population variability: important considerations in vaccine development
Jun 14, 2023
CTB Blog
EMA’s new pre-submission interactions model pilot: A fundamental shift toward submission readiness and predictable reviews
Sep 30, 2026
Case Study
Speed meets strategy: Delivering a critical FDA 1572 package in just seven days
Sep 9, 2026
Blog
Actioning the commitment letter: The PDUFA VIII changes that matter most to sponsors
Aug 25, 2026
Blog
Data without borders: Assessing China-only evidence for EMA approval – insights from ex-EMA and seasoned subject matter experts
Aug 19, 2026
Blog
The Next Frontier of ADC Development: Navigating an Evolving Regulatory Landscape
Aug 12, 2026
Webinar
From APAC to global: Designing data that travels
Jul 16, 2026
Blog
Regulatory submissions as a source of insight: How AI can amplify the value of our work
Jul 15, 2026
Blog
Accelerating first-in-human studies: Why the FDA’s Expedited IND pilot signals a new era for early development
Jul 6, 2026
CTB Blog
A credible global regulatory strategy is an early-phase imperative, not a late-stage commercial exercise
Jun 23, 2026
CTB Blog
Understanding FDA complete response letters: Why CMC readiness must become a strategic priority
Jun 18, 2026
Case Study
Case study: Repositioning first-in-human development at speed
Jun 8, 2026
Related Insights
Blog
Population variability: important considerations in vaccine development
Jun 14, 2023
CTB Blog
EMA’s new pre-submission interactions model pilot: A fundamental shift toward submission readiness and predictable reviews
Sep 30, 2026
Case Study
Speed meets strategy: Delivering a critical FDA 1572 package in just seven days
Sep 9, 2026
Blog
Actioning the commitment letter: The PDUFA VIII changes that matter most to sponsors
Aug 25, 2026
Blog
Data without borders: Assessing China-only evidence for EMA approval – insights from ex-EMA and seasoned subject matter experts
Aug 19, 2026
Blog
The Next Frontier of ADC Development: Navigating an Evolving Regulatory Landscape
Aug 12, 2026
Webinar
From APAC to global: Designing data that travels
Jul 16, 2026
Blog
Regulatory submissions as a source of insight: How AI can amplify the value of our work
Jul 15, 2026
Blog
Accelerating first-in-human studies: Why the FDA’s Expedited IND pilot signals a new era for early development
Jul 6, 2026
CTB Blog
A credible global regulatory strategy is an early-phase imperative, not a late-stage commercial exercise
Jun 23, 2026
CTB Blog
Understanding FDA complete response letters: Why CMC readiness must become a strategic priority
Jun 18, 2026
Case Study
Case study: Repositioning first-in-human development at speed
Jun 8, 2026